Some Potential Clinical Uses of KL and FL
| . | Comments . |
|---|---|
| Likely applications | |
| Ex vivo expansion/purging of progenitor/stem cell grafts | In combination with other early acting (stem cells) and lineage-selective cytokines (progenitors) to improve reconstitution and to purge tumor-contaminated progenitor/stem cell grafts. |
| Progenitor/stem cell mobilization | In combinations with other cytokines (GM-CSF, G-CSF, TPO, or others) to improve mobilization of progenitor/stem cells to peripheral blood to be used in transplantation. |
| Gene therapy | (1) In combination with other early acting cytokines to improve gene transfer to stem cells in vitro. (2) Mobilize/expand stem cells in vivo (see above) that might prove better targets for gene transfer. |
| Immunotherapy | (1) Ex vivo (KL and FL) and in vivo (only FL) expansion of DC for use as vaccine adjuvant. (2) In vivo antitumor activity of FL (via effects on DC and NK cells). |
| Additional potential applications | |
| Stem cell deficiencies | Potential diseases include aplastic anemia and myelodysplastic syndromes. |
| Pure erythroid aplasia (Diamond-Blackfan anemia) | KL might prove more efficient than FL due to the wide expression of c-kit and lack of flt3 on primitive erythroid progenitors. |
| Cytopenias after chemotherapy/bone marrow transplantation | G-CSF/GM-CSF are efficient at promoting neutrophil recovery, and TPO may prove efficient at enhancing platelet recovery. However, KL and FL might, in combination with G-CSF and/or TPO, be of benefit when primitive progenitor/stem cells are severely compromised. |
| Immunodeficiencies (HIV) | Adjuvant treatment of cytopenias. |
| . | Comments . |
|---|---|
| Likely applications | |
| Ex vivo expansion/purging of progenitor/stem cell grafts | In combination with other early acting (stem cells) and lineage-selective cytokines (progenitors) to improve reconstitution and to purge tumor-contaminated progenitor/stem cell grafts. |
| Progenitor/stem cell mobilization | In combinations with other cytokines (GM-CSF, G-CSF, TPO, or others) to improve mobilization of progenitor/stem cells to peripheral blood to be used in transplantation. |
| Gene therapy | (1) In combination with other early acting cytokines to improve gene transfer to stem cells in vitro. (2) Mobilize/expand stem cells in vivo (see above) that might prove better targets for gene transfer. |
| Immunotherapy | (1) Ex vivo (KL and FL) and in vivo (only FL) expansion of DC for use as vaccine adjuvant. (2) In vivo antitumor activity of FL (via effects on DC and NK cells). |
| Additional potential applications | |
| Stem cell deficiencies | Potential diseases include aplastic anemia and myelodysplastic syndromes. |
| Pure erythroid aplasia (Diamond-Blackfan anemia) | KL might prove more efficient than FL due to the wide expression of c-kit and lack of flt3 on primitive erythroid progenitors. |
| Cytopenias after chemotherapy/bone marrow transplantation | G-CSF/GM-CSF are efficient at promoting neutrophil recovery, and TPO may prove efficient at enhancing platelet recovery. However, KL and FL might, in combination with G-CSF and/or TPO, be of benefit when primitive progenitor/stem cells are severely compromised. |
| Immunodeficiencies (HIV) | Adjuvant treatment of cytopenias. |